Aimee Jackson, PhD

Chief Scientific Officer at Atalanta Therapeutics

Speaker

Aimee is currently the Chief Scientific Officer for Atalanta Therapeutics and has worked in the field of RNA interference and oligonucleotide therapeutics for 25 years. Aimee joined Atalanta as employee #3 and has been responsible for building and directing a fully integrated research organization to identify and develop divalent siRNAs for CNS indications. Prior to joining Atalanta, Aimee served as the Vice President of Research for miRagen Therapeutics, where she advanced 3 microRNA programs from initial concept to First-in-Human clinical trials in less than 5 years. These programs encompassed diverse therapeutic areas and comprised both microRNA mimics and inhibitors. All three programs successfully completed Phase 1 clinical trials, and two of these programs advanced to Phase 2 clinical trials. Prior to joining miRagen, she led preclinical research at Regulus Therapeutics and Merck/Rosetta, where she served as Molecular Profiling Lead for the development of siRNA-based therapeutics. Known for identifying siRNA off-target effects, she played a lead role in the identification of siRNA design and chemistry aspects for enhanced activity and specificity.

Aimee is known for being passionate about cutting-edge and innovative approaches to technology and medicine to improve patients’ lives.